COVID-19: No vaccine approved yet for clinical trials – NAFDAC

The National Agency for Food and Drug Administration and Control (NAFDAC) said it has not approved any vaccine for clinical trials to combat the COVID-19 pandemic.

Clearing the air on the rumours that clinical trials of Covid-19 vaccine will soon begin in African countries, including Nigeria, the agency stressed that before any clinical trial begins in the country, it must have been conducted in different countries, which may not happen before one year to eighteen months.

The Director General of NAFDAC, Prof. Mojisola Adeyeye, made this known in statement in Abuja.

According to her,“Please note, no vaccines have been approved for any clinical trial.

“That may not happen before one year to eighteen months, after clinical trials must have been conducted in different countries.

“This will be followed by rigorous in-country assessment in line with laid down protocols to further ensure safety and efficacy”.

She further disclosed that NAFDAC has granted conditional emergency use of medical devices (COVID-19 Antibody and Antigen Test Kits, PPEs, etc.) to diagnostic companies.

She further said:  “The current COVID-19 pandemic has necessitated that NAFDAC put measures in place to ensure access to health commodities that have the potential to impact positively on public health outcomes.

“These include, but are not limited to, diagnostics necessary to support public health infrastructure and guide the response necessary to combat and address the pandemic.

“The antibody test kits (IgG/IgM) can be used in COVID-19 confirmed individuals, who can then be tested at the designated centers using the antibody kits, to confirm that they have antibodies and as such may not be infected again.

“The antigen tests kits on the other hand, can detect the COVID-19 antigen in patients with or without symptoms. The results are only qualitative (positive or negative).

“There has been a global effort by innovative diagnostic companies to develop test kits to aid in detection of the virus in patients to guide the management of the disease.

“The Agency has recently received many requests for Emergency Use Authorisation for some of such diagnostic test kits to support the national response and ensure expanded testing capabilities”.